ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction.Nature communications · 2026Article
- Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.Cancer research · 2024Article
- cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer.NPJ breast cancer · 2024Article
- Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.Breast cancer (Dove Medical Press) · 2024Review
- Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.Nutrients · 2023Article
- Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.Oncogene · 2022Article
- The Novel Diagnostic Techniques and Biomarkers of Canine Mammary Tumors.Veterinary sciences · 2022Review
- Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.NPJ precision oncology · 2022Article
- Article
- LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers.Oncogenesis · 2021Article
- Article
- The requirement for cyclin E in c-Myc overexpressing breast cancers.Cell cycle (Georgetown, Tex.) · 2020Article
- Identification of potential markers for type 2 diabetes mellitus via bioinformatics analysis.Molecular medicine reports · 2020Article
- Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2020Review
- Article
- Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study.Frontiers in oncology · 2020Article
- Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer.Frontiers in pharmacology · 2020Review
- Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer.NPJ breast cancer · 2020Article
- Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle.American journal of translational research · 2020Review
- NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.Breast cancer research : BCR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Kelly K Hunt *Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cansu KarakasDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Min Jin HaDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anna BiernackaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Min YiDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Aysegul A SahinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Opoku AdjapongDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gabriel N HortobagyiDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Melissa BondyDepartment of Pathology Administration, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Patricia ThompsonDepartment of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
Kwok Leung CheungSchool of Medicine, University of Nottingham, Nottingham, UK.
Ian O EllisSchool of Medicine, University of Nottingham, Nottingham, UK.
Sarah BacusQuintiles Transnational Corp, Denver, Colorado, USA.
W Fraser SymmansDepartment of Pathology Administration, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Kim-Anh DoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Khandan Keyomarsi *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
University of Nottingham · GBBaylor College of Medicine · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MProteolytic Processing of Cyclin E in Breast CancerR01CA087548 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2001 to 2015
$4.1MRisk Prediction for ER Negative Breast Cancer RecurrenceR01CA172511 · NCI · BAYLOR COLLEGE OF MEDICINE · PI BONDY, MELISSA L., BREWSTER, ABENAA M · 2013 to 2017
$3.1MTargeting the cell cycle in triple negative breast cancerR01CA152228 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2011 to 2015
$2.3MNCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA087548NCI NIH HHS R01 CA152228NCI NIH HHS R01 CA172511
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell NucleusCyclin ECytoplasmDisease-Free SurvivalFemaleHumansMiddle AgedMolecular WeightNeoplasm Recurrence, LocalPrognosisBiomarkers, TumorCyclin EProtein Isoforms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.